Catch up on the top radiology content of the past week.
|Articles|June 7, 2000
ADAC to ship Skylight sometime after October
ADAC Laboratories has a first customer for its recently approved Skylight nuclear medicine camera: Cedars-Sinai Medical Center in Los Angeles.Cedars-Sinai placed an order for the $1 million imaging device, along with a C-PET positron emission
Advertisement
ADAC Laboratories has a first customer for its recently approved Skylight nuclear medicine camera: Cedars-Sinai Medical Center in Los Angeles.
Cedars-Sinai placed an order for the $1 million imaging device, along with a C-PET positron emission tomography system and three Forte gamma cameras, at the end of May. ADAC will begin delivering systems sometime in the company's fiscal year 2001, which begins in October.
The cameras will be installed in the hospital's S. Mark Taper Imaging Department. Nonprofit Cedars-Sinai's imaging department performs more than 264,000 examinations annually.
ADAC claims the gantry-free Skylight system is revolutionary in design. Its architecture allows gamma detectors to be mounted in a room structure, which removes limitations associated with the floor-based mechanical gantries of other nuclear medicine systems. ADAC received FDA approval to market the Skylight in May (SCAN 5/10/00).
Advertisement
Related to this article
While a new article raises provocative questions about the capability of photon-counting CT (PCCT) to perhaps replace diagnostic ICA, the real revolution with this modality is going beyond stenosis measurement to a renewed focus on the disease of atherosclerosis.
The use of adjunctive CT bone reading software in women with breast cancer detected between 8 to 22 percent more metastatic lesions for reviewing radiologists and reduced CT interpretation time by 50 percent or more, according to a new study.
Catch up on the top radiology content of the past week.
Catch up on the top radiology content of the past week.
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
Does fractional flow reserve (FFR) or quantitative plaque burden from CCTA provide greater prognostic insight into coronary disease?
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
2
Can MRI-Based AI Have an Impact in Reducing Unnecessary Prostate Biopsies?
3
The Reading Room Podcast: A Closer Look at New Research on 177Lu-Edotreotide for Treating GEP-NETs
4
How AI, Theranostics and More Empowered Patients Have Led to Significant Changes in Radiology
5